Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Synosia raises CHF32 million

This article was originally published in Scrip

Executive Summary

Synosia Therapeutics has raised CHF32 million ($29 million) in a series B private financing round led by Aravis Venture and Investor Growth Capital. It will use the funds to develop its six clinical-stage compounds acquired through strategic partnerships with Roche, Novartis and Syngenta. SYN-111 (rufinamide), an orally bioavailable sodium channel blocker for the treatment of anxiety acquired from Novartis, is currently in Phase II development. The company also has SYN-115, an adenosine A2A antagonist for the treatment of Parkinson's disease, and SYN-117 (nepicastat) for the treatment of drug dependency and post-traumatic stress disorder, in Phase II development. Jean-Philippe Tripet, managing partner of Aravis, will join Synosia's board of directors. He said that it was rare to see a private biotechnology company with compounds in four promising Phase II clinical trails. Other investors joining the board are Gosta Jonsson, independent scientific advisor to Investor Growth Capital; Guido Magni, formerly of Roche; Harry Welten, chief financial officer of Arpida; Ralf Rosenow, partner of BlumGrob Attorneys at Law; and Genghis Lloyd-Harris, partner of Abingworth.

Advertisement

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC007866

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel